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Abstract
Background: At the time of feasibility work and final design of the trial there was no randomised control trial evidence
for the long-term risks and benefits of hormone replacement therapy. Observational studies had suggested that long term
use of estrogen was likely to be associated, amongst other things, with reduced risks of osteoporosis and ischaemic heart
disease and increased risks of breast and endometrial cancer. Concomitant use of progestogens had been shown to
protect against endometrial cancer, but there were few data showing how progestogen might affect estrogen actions on
other conditions. Disease specific risks from observational studies suggested that, overall, long-term HRT was likely to
be beneficial. Several studies showed that mortality from all causes was lower in HRT users than in non-users. Some
secondary cardiovascular prevention trials were ongoing but evidence was also required for a range of outcomes in
healthy women. The WISDOM trial was designed to compare combined estrogen and progestogen versus placebo, and
estrogen alone versus combined estrogen and progestogen. During the development of WISDOM the Women's Health
Initiative trial was designed, funded and started in the US.
Design: Randomised, placebo, controlled, trial.
Methods: The trial was set in general practices in the UK (384), Australia (94), and New Zealand (24). In these practices
284175 women aged 50–69 years were registered with 226282 potentially eligible. We sought to randomise 22300
postmenopausal women aged 50 – 69 and treat for ten years. The interventions were: conjugated equine estrogens,
0.625 mg orally daily; conjugated equine estrogens plus medroxyprogesterone acetate 2.5/5.0 mg orally daily; matched
placebo. Primary outcome measures were: major cardiovascular disease, osteoporotic fractures, breast cancer and
dementia. Secondary outcomes were: other cancers, all cause death, venous thromboembolism and cerebro-vascular
disease.
Results: The trial was prematurely closed during recruitment following publication of early results from the Women's
Health Initiative. At the time of closure, 56583 had been screened, 8980 entered run-in, and 5694 (26% of target of
22,300) randomised. Those women randomised had received a mean of one year of therapy, mean age was 62.8 years
and total follow-up time was 6491 person years.
Discussion: The WISDOM experience leads to some simple messages. The larger a trial is the more simple it needs to
be to ensure cost effective and timely delivery. When a trial is very costly and beyond the resources of one country,
funders and investigators should make every effort to develop international collaboration with joint funding.
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Background
The Women's International Study of long Duration Oes-
trogen after Menopause (WISDOM) developed from a
joint initiative of the UK Medical Research Council (MRC)
and the UK Departments of Health. At the start of the
WISDOM trial observational studies had suggested that
long term use of estrogen was likely to be associated with
a reduced risk of osteoporosis [1] and ischaemic heart dis-
ease (IHD) [2] and an increased risk of breast cancer [3]
and endometrial cancer [4]. While concomitant use of
progestogens could protect against endometrial cancer
[4], it was not clear how progestogen might affect the
action of estrogen on IHD or other conditions [5-11]. In
addition to the main benefits of HRT, observational data
suggested that several other conditions might benefit
from long-term HRT. These included: stroke [5,6]; cogni-
tive function, Alzheimer's disease and ischaemic vascular
dementia [12,13] tooth loss [14] periodontal disease [15]
and oral discomfort [16]; osteoarthritis [17,18] colorectal
cancer [19,20]; age-related macular degeneration [21] and
possibly cataract [22]. There was also evidence of further
risks including: increased risk of deep vein thrombosis
and pulmonary embolism [23-27]; ovarian cancer [28]
and tinnitus [29] and an exacerbation of some autoim-
mune diseases [30]. The disease specific risks from obser-
vational studies suggested that the overall effect of long-
term HRT was likely to be beneficial and several studies
showed that mortality from all causes was lower in HRT
users than in non-users [31,32]. However, it was acknowl-
edged that since observational studies, even when well
controlled, may be subject to bias and confounding still
not recognised or allowed for and that the true sizes of the
effects may differ significantly [33]. The true balance
between the risks and benefits of hormone replacement
therapy (HRT) could only be ascertained by a randomised
controlled trial.
The need for a randomised controlled trial to investigate
the long-term effects of (HRT) was first proposed by an
MRC ad hoc group in July 1989. Feasibility studies pilot-
ing several designs, and overseen by an MRC Working
Party, were undertaken by the MRC General Practice
Research Framework, starting in the UK in March 1990
and in Ireland and the Netherlands, partly funded by the
European Union (EU) Framework Biomedical and Health
Research Programme, in 1992. These indicated that a trial
would be acceptable to women and their doctors and that
recruitment was feasible [9,10,33]. We submitted a proto-
col for a full scale trial to the MRC in early 1993. The
design incorporated comparison of two types of estrogen
and two types of progestogen in recently menopausal
women and required international co-operation both to
recruit and to fund the trial. To reduce costs the MRC
Working Party recommended including women from age
50 to 64 years, so that events could be accrued more
quickly, and limiting the comparisons to one estrogen
and one progestogen. An MRC Trial Development Group
was set up to consider ways of refining the protocol, thus
reducing the scale and the cost of the proposed trial.
Meanwhile, the US Women's Health Initiative (WHI) trial
using the Postmenopausal Estrogen/Progestin Interven-
tions (PEPI) trial [8] as evidence of feasibility was fully
funded and began recruitment [35]. The WHI trial
recruited women aged 50 to 79 years and compared con-
jugated equine estrogen (CEE) with placebo in hysterect-
omised women and CEE plus medroxyprogesterone
acetate (MPA) with placebo in women with a uterus.
The MRC Trial Development Group proposed a UK com-
ponent with minimally acceptable power and interna-
tional collaboration to recruit a larger sample to achieve
higher power. We submitted an application, jointly to
MRC and the UK Departments of Health, in November
1993 for the UK component and began discussions with
several pharmaceutical companies for trial medication.
Wyeth Ayerst US was the only company willing to provide
active and placebo medication. This was the same estro-
gen and progestogen as used in the WHI trial plus
matched placebo. It took almost three years for a decision
to fund the UK component of WISDOM to be reached
because the cost was high and many menopause clini-
cians opposed the trial, claiming that the cardiovascular
benefit was proven, the effect on breast cancer over-esti-
mated and the results with CEE and MPA unlikely to be
relevant to clinical practice ten years hence. We submitted
a business case for the trial showing that as long as the
trial gave a clear answer to the question of balance of risks
and benefits costs were justified. MRC conducted an
extensive independent international peer review includ-
ing a separate review looking at the future relevance of
results with CEE and MPA. Funding of £21 million for the
UK component in 18,000 women was agreed in August
1996. Set up work for the trial in around 400 UK general
practices began in 1997 and recruitment in 1999.
An application was made to the EU Framework IV pro-
gramme for funds for the international arm of WISDOM
requesting full cost funding for some European countries
plus co-ordination funding for others and, by reciprocal
arrangement, for Australia and South Africa. Despite scor-
ing highly on scientific grounds the application was
rejected as it was considered that the WHI trial would
answer the questions posed. This decision blocked any
contribution to WISDOM from Europe. In 2001, some
UK funding was transferred to Australia and New Zealand
and, supplemented by funding within these countries,
international recruitment began in 2001.
BMC Women's Health 2007, 7:2 http://www.biomedcentral.com/1472-6874/7/2
Page 3 of 17
(page number not for citation purposes)
Evidence emerging during conduct of the trial and impact 
on WISDOM
During the conduct of WISDOM three, randomised, con-
trolled trials reported on the risks and benefits of HRT in
postmenopausal women with pre-existing cardiovascular
events [36-38]. The HERS trial demonstrated that com-
bined HRT increased the risk of IHD [36], the EVTET trial
that estrogen increased recurrence of venous thromboem-
bolism [37] and Viscoli et al that estrogen increased risk
of stroke [38].
In June 2002 the arm of the WHI trial in women with a
uterus was discontinued early after an average of 5.2 years
of follow-up when the results suggested that risks were
likely to outweigh benefits. Women taking estrogen and
progestogen (combined HRT) had an increased risk of
coronary heart disease, stroke, pulmonary embolism and
breast cancer, and a decreased risk of hip fracture and
colorectal cancer, compared with placebo [39].
The UK MRC reviewed the data from the WHI and other
studies that had reported since WISDOM began and con-
sidered the case, made by the investigators with the sup-
port of the WISDOM Trial Steering and Data Monitoring
Committees, to continue WISDOM. In October 2002
MRC decided to close the trial. Funds were made available
for closure visits and for some statistical support but, inev-
itably, key members of the team found other positions
before the WISDOM data could be coded and analysed.
This has resulted in long delays in the preparation of
papers reporting the main findings from WISDOM. These
are now nearing completion and it is hoped that the full
data set which also contains much cross sectional data of
potential interest will be made widely available. This
paper describes the protocol for the trial, the difficulties
encountered in recruiting at the expected rate and changes
made to increase the rate of recruitment.
Evidence emerging since the closure of WISDOM
The WHI reported that combined HRT did not appear to
protect against development of dementia in women who
entered the trial over age 65 years [40] and had no clini-
cally meaningful effect on health related quality of life in
postmenopausal women [41]. The WHI trial in hysterect-
omised women randomised to estrogen or placebo was
closed prematurely [42] after an average of 6.8 years of fol-
low up. Women taking estrogen had an increased risk of
stroke compared with those taking placebo but neither
cardio-protection nor increased breast cancer, had been,
or were considered likely to be, found.
The WHI data on breast cancer in women taking estrogen
appears to conflict with observational studies suggesting
that both combined and estrogen only HRT increase
breast cancer in a general population. The observational
studies do however report that the increased risk is greater
for combined HRT [43,44] and that the effects of HRT are
smaller in obese than in thinner women [43]. Since over
half the women in the WHI estrogen trial were obese this
may account for the lack of effect on breast cancer.
The trial results emerging since WISDOM began and data
from large observational studies [44-46] have led to
revised guidelines on the use of HRT [47-49] which is now
recommended only for short term use to relieve meno-
pausal symptoms. However some have questioned
whether the results in the populations studied can be gen-
erally applied to recently postmenopausal women [50].
The WHI trial recruited postmenopausal women aged 50
to 79 years, mean 63.3 years, and thus largely reflects the
long-term effects of HRT in older women [35]. The
women in the WHI trial, particularly in the estrogen only
arm, were also, more overweight than average, compared
with the US national population figures and some already
had documented cardiovascular events whilst amongst
many others there was a high prevalence of established
cardiovascular risk factors at entry [50]. The other trials
reporting effects of HRT on cardiovascular disease were
secondary prevention trials [36-38]. A meta-analysis of 30
randomised controlled trials conducted between 1966
and 2002 assessed mortality associated with HRT by age
above or below 60 at trial entry. Compared with placebo
a significant reduction in mortality was seen in those ini-
tiating HRT under age 60 but not in those initiating HRT
after age 60 [51].
Study objectives
The aim of the WISDOM trial was to contribute to estab-
lishing the long-term balance between benefits and risks
of hormone replacement therapy (HRT). The design
allowed for two comparisons: between HRT, mainly com-
bined HRT, and placebo; and, in hysterectomised women
only, between estrogen alone and combined HRT.
The main objectives were to estimate the effects of HRT on
the incidence of:
• major cardiovascular disease;
• osteoporotic fractures;
• breast cancer;
• dementia; and
• the short and long term effects on quality of life and psy-
chological well-being.
Secondary objectives were to estimate: the effect of HRT
on stroke, venous thrombosis, depression, osteoarthritis,
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other cancers including colorectal and ovarian cancer,
age-related macular degeneration, cataract, retinal vein
occlusion, dry eye syndrome, tooth loss, periodontal dis-
ease, auto-immune diseases and tinnitus; and the health
economic implications of HRT usage.
Methods
Trial design
WISDOM was designed as a double blind randomised
placebo controlled trial. The design allowed for two com-
parisons: the main comparison between HRT, mainly
combined HRT, and placebo; and in hysterectomised
women only, between estrogen alone and combined HRT.
The different stages of the trial from identification of
potential participants through to the closure visit are sum-
marised in Figure 1 and the data collected at the different
stages is outlined in Additional file 1.
Setting
The trial was undertaken in general practices in the UK,
Australia and New Zealand. The co-ordinating centre of
the UK Medical Research Council (MRC) General Practice
Research Framework (GPRF) in London was responsible
for overall development and co-ordination.
In the UK, recruitment was nationwide through 384
group general practices that were part of the MRC GPRF.
In Australia recruitment was from 91 general practices in
three states with overall co-ordination from the Depart-
ment of Obstetrics and Gynaecology, University of
Adelaide and satellite centres at the Faculty of Health at
the University of Newcastle and the Baker Medical
Research Institute in Melbourne. In New Zealand recruit-
ment was from 24 general practices in three areas with
overall co-ordination from the Department of General
Practice, Wellington School of Medicine and Human
Health and satellite centres in Auckland and Christchurch.
In each general practice one clinician was responsible for
the day-to-day conduct of the trial though individual GPs
retained ongoing clinical responsibility for their own
patients.
Participants
Postmenopausal women aged 50 to 69 years at randomi-
sation were eligible for the trial. Postmenopausal was
defined as no menstrual period in the last twelve months
or having had a hysterectomy. Women who had started
taking HRT before their menstrual periods had stopped
were considered eligible when they had been taking HRT
for 12 months.
The exclusion criteria for randomisation were:
• For the placebo controlled components: oral or
transdermal HRT use in the last six months, ever use of
HRT implant in women with a uterus, HRT implant
inserted in last eight months in women with a hysterec-
tomy.
• History of endometriosis (hysterectomised or non-hys-
terectomised woman) or endometrial hyperplasia in a
woman with a uterus.
• History of invasive breast cancer, lobular carcinoma in-
situ (LCIS), ductal carcinoma in-situ (DCIS), Paget's dis-
ease of the nipple or atypical hyperplasia of the breast.
• Known BRCA1 or BRCA2 mutation carrier.
• History of melanoma.
• Invasive cancer at any other site apart from basal and
squamous cell skin cancer within the last 10 years.
• History of meningioma.
• Myocardial infarction, cerebrovascular accident, sub-
arachnoid haemorrhage or transient ischaemic attack
within the last six months.
• History of currently active liver disease or chronic liver
disease but excluding Hepatitis A unless currently active.
• Evidence of severe current renal impairment.
• History of gall bladder disease in a woman who had not
had a cholecystectomy or of gallstones following a chole-
cystectomy.
• History of deep vein thrombosis, pulmonary embolism
or retinal vein occlusion.
• Positive thrombophilia screen (Factor V Leiden or pro-
thrombin mutations, Protein C, Protein S or anti-
thrombin III deficiencies, APC resistance, dysfibrinoge-
naemia or antiphospholipid antibodies).
• Otosclerosis.
• Porphyria.
• History of hepatitis B, hepatitis C or HIV (not an exclu-
sion in New Zealand).
• Currently pregnant.
• Currently taking or has taken contraceptive drugs in the
last 12 months.
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Flowchart of trial procedures in WISDOMigure 1
Flowchart of trial procedures in WISDOM. (1) In UK explanation given on individual basis. In NZ and Australia group ses-
sions held and individual interviews held later with women who indicated interest in the trial. (2) In Australia tablets not held or 
issued by individual general practices. Participants collected trial medication from the co-ordinating centre's pharmacy. (3) In 
Australia blood samples taken at co-ordinating centre and results sent to GP.
          Postal/telephone invitation to screening at clinic or surgery
       Four weeks to consider participation 
Screening (1)
Full explanation of trial with background information (oral and written) on the 
menopause and HRT. 
Demographic data, medical history, current medical conditions, current contra-
indicated medication, symptoms questionnaire and quality of life on single
scale, BP, height and weight.
Patient identification 
Search of age-sex registers in primary care. 
In UK and NZ ineligible women excluded after a search of patient records.
In Australia all women in age range invited to group screening
Follow-up during run-in (3)
2 visits after approximately 3 and 7 weeks
Visit one, tablet count, symptoms questionnaire, diary and bleeding check, BP, 
weight.
Visit two, as visit one plus blood sample for triglycerides, eligibility, willingness
to enter randomised treatment
Follow-up during randomised treatment (2)
Visits at 4, 14, 27, 40 and 52 weeks, 6 monthly thereafter
At each visit: tablet count, diary and bleeding check, medical history, current 
medical conditions, current medication, symptoms questionnaire, BP and 
weight
Annually: medical examination plus height, waist, hip, urine test, quality of life 
and health care questionnaires.
Tablets issued as required
Entry to randomised treatment medical - trial week 0 (2)
Diary and bleeding check, medical history, current medical conditions, current 
medication, symptoms questionnaire, quality of life and health care (use of 
services) questionnaires, BP, weight, height, waist, hip, urine test 
Tablets issued
Run-in entry medical and informed consent (2)
Medical examination, medical history, current medical conditions, current
medication, symptoms questionnaire, BP, weight, urine test for glucose, blood,
protein.
BMC Women's Health 2007, 7:2 http://www.biomedcentral.com/1472-6874/7/2
Page 6 of 17
(page number not for citation purposes)
• Current triglyceride level (fasting) > 5.5 mmol/l.
• Active participant in any other intervention trial likely to
affect trial outcomes.
• Taking tamoxifen, toremifene, raloxifene or any other
selective oestrogen receptor modulator (SERM).
• Other conditions/circumstances where the general prac-
titioner judged that it would not be possible to obtain
fully informed consent and/or successfully complete trial
procedures.
Identification of potential participants
Women aged 49–69 years were identified from the gen-
eral practice registers (Figure 1). Identifying women aged
49 years allowed a maximum of one year for contact,
screening and a run-in phase prior to randomisation at
50. The women were assigned WISDOM study numbers
and, where possible, their medical records were searched
to identify any recorded evidence of ineligibility and fac-
tors in the medical history potentially associated with trial
outcomes. These searches were conducted by practice
nurses and, in data passed to the researchers, potential
participants were identified only by study number. The
information collected is listed in Additional file 1.
One reason for collecting the medical history of all
women in the eligible age range was to be able to assess
the generalisability of the results of the trial in the ran-
domised population to that of the registered population.
While this was valuable, it was time consuming, and
affected the rate of recruitment between 1999 and 2001.
The randomisation stage of the trial was not started until
January 2001. In July 2001, once sufficient data on which
to comment on generalisability had been obtained from
the eligible population, the full note search of every
woman eligible for the trial was replaced by a quicker eli-
gibility check. From this point the trial nurses checked the
patients' medical records against a list of the ineligibility
criteria and recorded reasons for ineligibility.
Screening
In the UK, starting with the older age band first, those who
were potentially eligible for the trial were contacted by a
letter from their general practitioner and invited to attend
a screening session with a research nurse at their practice,
The women were told that the practice was taking part in
a large study on the health of post-menopausal women
that included a long-term trial of HRT. They were invited
to the surgery to discuss their health, the menopause, the
benefits and risks of HRT, the trial and their possible par-
ticipation in the trial. If the women preferred, these
screening interviews could also be conducted in their
homes.
In Australia, patients were first invited to group sessions to
learn about HRT and the trial while in the UK and New
Zealand these aspects were covered as the first part of the
screening interview. Many women attended for a screen-
ing interview from general interest and to discuss their
health, but had no intention of entering a trial; others
were initially interested but once they were given more
information about the trial, decided not to participate.
This was another factor affecting recruitment. From May
2002 the patient information leaflet was included with
the invitation letter from the GP, giving more information
about the trial so that women who definitely had no
intention of participating were less likely to attend a
screening interview. This increased the rate at which those
likely to participate could be screened and recruited.
At the screening interview women completed a nurse
administered screening questionnaire covering demogra-
phy, medical history, including trial exclusions and
known risk factors for the trial end-points, current medi-
cal conditions, contra-indicated medication, symptoms
(Figure 2), recent cervical screening and mammography
and overall quality of life. Blood pressure, height and
weight were measured. From May 2002, to reduce the
time taken to conduct a screening interview, height and
weight were not measured and details of ethnic origin
were not collected. Collection of full information on life-
style, fractures and current medical conditions was
deferred until the randomisation visit.
Any discrepancies between data previously extracted from
the patient's notes and the patient's recall were identified
and highlighted by the computerised patient manage-
ment program so that the nurse could resolve them, if nec-
essary by consulting the GP. Data collected are listed in
Additional file 1.
Potential participants were given a full explanation of the
menopause, current knowledge of the risks and benefits of
HRT, the rationale for the trial, details of the trial includ-
ing all procedures involved and visits required. The
explanatory materials were developed in collaboration
with a lay panel of women.
Those women eligible on the basis of the questionnaires
were invited to consider participating in the trial. Women
with an intact uterus or sub-total hysterectomy, taking
HRT and unwilling to discontinue for a washout period
before randomisation, were excluded. Other potentially
interested women were told they would be assigned to
one of three strata (figure 3):
1. Women with an intact uterus or sub-total hysterectomy
not taking HRT were assigned to stratum one and ran-
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WISDOM trial symptoms questionnaireFigure 2
WISDOM trial symptoms questionnaire.
Have you had any of the following symptoms during the past 4 weeks?
Please indicate how bothersome the symptom was for you based on the following definitions:   
MILD   =  symptom did not interfere with my usual activities. 
MODERATE =  symptom interfered somewhat with my usual activities. 
SEVERE =  symptom was so bothersome that my usual activities could not be 
                              performed. 
SYMPTOM
Symptom 
did not 
occur
Mild Moderate Severe
Hot flushes 
Night sweats 
Insomnia
Feeling depressed 
Feeling anxious 
Dizziness 
Aching joints or muscles 
Tiredness
Headache
Migraine
Irritability / mood swings 
Heart racing or skipping beats 
Dry skin or scaling 
Vaginal or genital dryness 
Vaginal or genital itching or irritation 
Vaginal or genital discharge 
Pain or burning while urinating 
Breast tenderness 
Leg cramps / calf pain in one leg only 
Leg cramps in both legs 
Swelling of one leg only 
Swelling of both legs 
Nausea
Abdominal cramps 
Bloating
Skin rash / itching 
Crawling feelings under skin 
Any trouble seeing that is not 
corrected by glasses or contact lenses 
Other: please specify 
1.
2.
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domised to combined estrogen and progestogen replace-
ment therapy or placebo.
2. Hysterectomised women taking, and wishing to con-
tinue taking, HRT were assigned to stratum two and ran-
domised to estrogen only HRT or combined HRT.
3. Hysterectomised women not taking HRT were assigned
to stratum three and randomised to estrogen only HRT or
combined HRT or placebo.
They were given clear written explanation of the main
points covered in the interview and an appointment was
arranged two to four weeks later for a medical examina-
tion to enter the run-in phase of the trial and were asked
to cancel this if they decided not to proceed. All women
were asked for their written consent for their medical and
national records to be used in the future and for these
records and their trial data to be passed to the researchers.
Run-in
To ensure that they were fully committed to the trial
before randomisation and had no reaction to the excipi-
ents in the trial medication, participants were asked to
complete a run-in period of approximately twelve weeks.
At the entry to run-in visit the nurse recorded symptoms,
blood pressure, weight, urinary protein, glucose and
blood and checked that the woman remained eligible for
the trial (see Additional file 1). The GP conducted a gen-
eral medical examination and made the decision on eligi-
Treatment allocation in the WISDOM trialFigure 3
Treatment allocation in the WISDOM trial.
(Stratum 1)   (Stratum 2)   (Stratum 3) 
ERT – estrogen replacement therapy
PERT – progestogen plus estrogen
PL – placebo 
* includes sub-total hysterectomy
PERT PLERTPERTERTPLPERT
Current HRT No Current 
HRT
No Current 
HRT
Current HRT
(exclude)
Total hysterectomy With a uterus* 
Post menopausal 
women aged 50-69
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bility. The nurse ensured that the procedures for the trial
and possible risks and benefits were understood by the
women and that all questions had been answered.
Those willing to enter the trial gave written informed con-
sent and were issued with tablets for the run-in phase. All
women took medication during the run-in: women who
were eligible for the placebo controlled randomisation
(strata 1 and 3) took placebo; those who were not (stra-
tum 3) took estrogen only HRT.
Participation in the National Breast Screening Pro-
grammes was encouraged but was not mandatory; advice
and information on breast awareness was given. Women
with a uterus were given diaries to record any vaginal
bleeding, concurrent medication and illnesses. All
patients received a card stating that they were in the trial
with contact details for the practice, the co-ordinating cen-
tre and, for use by medical staff, the telephone number for
the 24 hour emergency code break.
There were two visits to the surgery during the run-in
period, at approximately three and eight weeks after entry,
mainly to check on tablet compliance and ensure that the
woman remained eligible (Table 1). At the second run-in
visit, those reaching 80% compliance were invited to enter
the randomised phase of the trial. If patients were willing
to enter but had not reached 80% compliance one further
run-in was permitted.
In the UK these women were asked to give a blood sample
to assess the last criterion for eligibility, a fasting triglycer-
ide level < 5.5 mmol/l, and to provide samples for future
analyses. A 25 ml non-fasting blood sample was taken ini-
tially: 5 ml for immediate estimation of triglyceride and
cholesterol levels and 20 ml to store as serum, red blood
cells, buffy coat and plasma for future analyses. Samples
were prepared at the practices and posted to arrive within
24 hours at the trial co-ordinating centre for analysis.
Patients with a non-fasting triglyceride level > 5.5 mmol/
l were recalled for a second triglyceride measurement fol-
lowing an overnight fast. Patients with fasting triglyceride
levels ≥ 5.5 mmol/l were excluded from the trial and
advised to consult their GP. In Australia and New Zea-
land, this criterion for eligibility was waived. Women who
were unwilling to give a blood sample in the UK could
enter the trial without a blood sample if their GP had
agreed eligibility.
Randomisation
After the second run-in visit women who were eligible and
willing to participate were randomised centrally and
appropriate medication dispatched to the practice in time
for the baseline randomisation visit. Participants were
assigned to treatment in accordance with the schema at
Figure 3 using a computer based, stratified block ran-
domisation program to ensure that within each stratum
the treatment groups were of virtually equal size. The strat-
ification was based on hysterectomy status and HRT use at
the time of randomisation. In stratum one, women with a
uterus were randomised to combined HRT therapy using
a block size of 16. In stratum two, hysterectomised
women who were only prepared to take active treatment
were randomised to estrogen only HRT or combined HRT
using a block size of 16. In stratum three, hysterectomised
women were randomised to estrogen only HRT, com-
bined HRT or placebo using a block size of 24.
The baseline questionnaire at the randomisation visit (see
Additional file 1) covered risk factors, possible adverse
events, all outcomes, quality of life and other medical his-
tory to check that they remained eligible. Use of health
services and details of the severity of certain conditions eg,
systemic lupus erythematosus were obtained from the
patients' notes. The nurse measured height, weight, and
waist and hip circumference using standard operating
procedures and the GP then made a final decision on eli-
gibility. A patient was recorded as entering randomised
treatment if she left the surgery with her first pack of ran-
domised treatment tablets.
Blinding and protection from bias
As far as possible, the trial was conducted in a double-
blind manner. The treatment assignment was directly
accessible only to the computer officer responsible for the
randomisation, the trial statisticians and the staff supply-
ing a 24 hour code break service. Computer generated lists
were sent to the drug dispensing manager along with
patient labels. Active and placebo medications were
matched for size, colour and taste. Within each stratum
labelling and packaging was identical and randomly gen-
erated tablet identification codes were used so that the
participant, the nurse and the GP were blinded to the
treatment allocation. No-one involved with assessment of
outcomes was aware of treatment assignment. During the
trial it was not possible to maintain full blindness as
reports of vaginal bleeding or spotting triggered a code
break and an investigation to ensure that any abnormal
bleeding was not overlooked.
Interventions
Estrogen-only HRT was conjugated equine estrogens (Pre-
marin, Wyeth Ayerst), 0.625 mg orally daily. Combined
progestogen and estrogen HRT was conjugated equine
oestrogens as above plus medroxyprogesterone acetate
(MPA) 2.5 mg orally daily (Prempro, Wyeth Ayerst US).
Women with a uterus within three years of their last
period, or aged 50–53 years, or aged 54 or over with unac-
ceptable breakthrough bleeding took a higher dose of 5.0
mg MPA (Premique, Wyeth Ayerst). Women who experi-
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enced unacceptable intermittent spotting or bleeding with
combined HRT containing 5.0 mg MPA were offered open
label Premique cycle (Premarin 0.625 mg orally daily plus
MPA 10 mg orally for the last 14 days of a 28 day cycle).
Women could choose to remain on Premique cycle for the
remainder of the trial or could return to their continuous
combined treatment. Estrogen-only HRT, combined HRT
and matched placebo containing the same excipients were
prepared and supplied by Wyeth Ayerst US.
Follow-up
It was planned to recruit women over a three year period
and to end the trial nine years after the last participant was
randomised giving a median of 10.5 years follow up, and
a maximum of 12 years. Women were to be seen at their
general practice at 4, 14, 27, 40 and 52 weeks and then 6
monthly. Nurses contacted participants between visits, by
telephone, to provide advice and support as required. A
final visit was to take place as soon as possible after the
closure of the trial.
Because of the decision in October 2002 to close the trial
early when the WHI results indicated that the likely bal-
ance of risks and benefits of HRTwas unfavourable the
median follow up time for WISDOM was 11.9 months
(IQR: 7.1 months to 19.6 months).
Patient compliance was assessed at each visit by tablet
count. At the annual visit information was collected on
risk factors, possible adverse events, all outcomes and on
other medical history to check that patients remained eli-
gible (see Additional file 1). At other visits information
was collected on risk factors, possible adverse events, pri-
mary and secondary outcomes and on other medical his-
tory to check that patients remained eligible (see
Additional file 1). There was provision for recording infor-
mation received by the nurse or the GP from the patient,
and with the patient's permission, from a friend or a rela-
tive between follow-up visits. A further check of general
practice medical records was made annually.
Outcomes were assessed at face to face interviews between
the patient and the nurse, using validated questionnaires
wherever possible, and entering data directly onto laptop
computers using a suite of software specially designed for
the trial which included a real time patient management
system in accordance with the protocol. Electronic data
checking at the time of collection incorporated extensive
checks for plausibility, consistency and completeness.
Data were sent to the co-ordinating centre within one
week of collection by modem link within the UK and via
a standard File Transfer Program server site from Australia
and New Zealand. A member of the study team, who was
blinded to treatment allocation, obtained any data
needed to confirm a clinical event from the GP, hospital
or coroner.
It had been planned to ascertain fatal end-points and can-
cer registrations in the UK via the National Health Service
Central Register, in Australia via the National Death Index
database and in New Zealand via National Health Index
number tracing, death registrations, hospital records and
the New Zealand Cancer register but with the early closure
this was not pursued.
To fully assess the long-term effects of HRT and to investi-
gate changes following discontinuation of treatment, fol-
low up by medical records in the general practice and
national records had been planned for a further five years
after treatment but following closure these plans were
abandoned.
Outcomes
The primary outcomes were:
• major cardiovascular disease, defined as the sum of one
or more of fatal and non-fatal myocardial infarction,
unstable, hospitalised angina and sudden coronary death;
• osteoporotic fractures (hip, wrist and all fractures other
than skull, face, cervical spine, fingers and toes);
• incidence of breast cancer; and
• quality of life and psychological well-being;
Secondary outcomes were:
• breast cancer mortality;
• other cancers, incidence and mortality;
• venous thromboembolism (deep vein thrombosis, pul-
monary embolism, retinal vein occlusion; and
• cerebro-vascular disease.
The following conditions were also investigated: depres-
sion; incontinence; symptomatic arthritis; tooth loss; per-
iodontal disease; tinnitus; asthma; low back pain; age-
related macular degeneration; cataract; and dry eye syn-
drome. Use of health services was recorded to allow an
estimate of the health economic implications of HRT
usage.
Health economic analysis
It had been planned to evaluate the health economic
implications of HRT by estimating, and modelling where
necessary, costs of treatment, costs of conditions pre-
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vented or caused by HRT, costs of all use of health care
and indirect costs such as time lost from work/usual activ-
ities and social security implications. Overall cost effec-
tiveness was to be calculated as costs per Quality Adjusted
Life Year (QALY) gained using the quality of life measured
by the EuroQol. In the light of the early closure this anal-
ysis did not proceed.
Dementia and cognitive decline sub-study
In an add-on study in sub-samples of WISDOM partici-
pants, the effects of HRT on the incidence and progression
of dementia and on the onset and progression of cognitive
decline were assessed. This work was led by Professor Mar-
tin Prince (Institute of Psychiatry, London), Professor Feli-
cia Huppert (Psychiatry, Cambridge) and Dr Marcus
Richards (University College, London) and will be
described in a separate publication.
Confirmation of outcomes
Primary and secondary clinical outcomes were reviewed
blind to treatment allocation. For cardiovascular disease,
cerebrovascular disease, venous thromboembolism and
cancers this was done by an independent assessor. For
fractures the assessment was done by a member of the
study team with a 10% sample reviewed by an independ-
ent assessor.
Adverse events
An adverse event was defined as any untoward medical
occurrence regardless of whether a causal relationship
with trial treatment was suspected. The event was classi-
fied as serious if it was life-threatening, required inpatient
hospitalisation or prolongation of existing hospitalisa-
tion, or caused significant or persistent disability or inca-
pacity. An unexpected adverse event was an experience
not previously reported (in nature, severity or incidence)
in connection with the trial treatment. For confirmed seri-
ous adverse events which were trial exclusions, the proto-
col required either a permanent or a temporary
interruption of trial treatment (see Additional file1).
Where the protocol did not specify a course of action the
nurse informed the GP and the trial clinician by memo
and they liaised to decide what action to take. Whenever
possible, the GP and clinician remained blind to treat-
ment allocation. For minor adverse events, for example
those recorded on the symptoms questionnaire, the nurse
and, if necessary, the GP, advised palliative treatments,
using guidelines, with the aim of keeping the patient in
the trial on their randomised treatment. New onset
migraine and current thrombophlebitis triggered a tem-
porary interruption of treatment.
Vaginal bleeding in women with a uterus
Intermittent vaginal bleeding was expected as a temporary
side effect of continuous combined HRT in some women
with a uterus randomised to PERT. Bleeding in women
with a uterus was monitored by asking the women to
complete a daily diary noting episodes of bleeding accord-
ing to the following categories:
• spotting – spotting/streaking not requiring sanitary pro-
tection;
• light – small amount of bleeding requiring some protec-
tion;
• moderate – less than a normal period;
• severe – normal period or heavier;
and recording any concurrent medical conditions, medi-
cation and whether trial medication had been missed.
The diaries were monitored at scheduled visits and
between scheduled visits women were asked to telephone
the trial nurse to report bleeding. The trial nurse recorded
occurrence of bleeding, severity, duration and whether
bleeding was continuous or intermittent.
At the beginning of the trial, best practice advice suggested
that to ensure that pathological bleeding was not over-
looked, all reports of vaginal bleeding continuing for at
least four weeks (continuous or intermittent) or bleeding
over a shorter period which was considered to be severe,
continuous or rapidly worsening, should trigger a request
by the trial nurse for a break in the treatment code. Those
taking placebo would then be referred to the GP, those
taking combined HRT with 2.5 mg MPA offered 5.0 mg
MPA, and those already taking 5.0 mg MPA asked to con-
tinue taking trial treatment for a further six weeks. Then, if
bleeding continued, participants would be referred to the
GP for investigation. If nothing abnormal were found,
participants would be offered second line treatment with
Premique Cycle. Women reporting only spotting would
be monitored without a code break and the advice of the
GP sought. This approach resulted in many women with-
drawing themselves from randomised treatment as they
were not prepared to wait for a protocol code break.
In January 2001, after consulting with the Steering and
Data Monitoring Committees, procedures for the man-
agement of bleeding were revised to reduce withdrawals
from the trial
To ensure that pathological bleeding was not overlooked,
all reports of vaginal bleeding, including spotting, trig-
gered an immediate break in treatment code. Patients
were asked to continue on trial medication during an
investigation of bleeding.
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• Bleeding that started on placebo treatment
Women randomised to placebo were referred immedi-
ately to their GP for investigation in line with their usual
clinical practice.
• Bleeding that started on active treatment
The management of women on active treatment
depended on when bleeding occurred relative to treat-
ment and previous amenorrhoea.
• Bleeding that started within 90 days on active treatment.
Vaginal bleeding is very common in the first few months
on continuous combined hormone replacement therapy
but usually resolves. Women with bleeding starting in the
first 90 days of active treatment (excluding any treatment
interruptions) were referred to their GP only if they or
their nurse were concerned. Women taking 2.5 mg MPA
were offered a dose increase to 5 mg as soon as bleeding
was reported. Women already on 5 mg MPA had no
change to their medication. Patients were monitored by
the nurse for 90 days from the date bleeding started. Any
woman who experienced vaginal bleeding after the 90-
day monitoring period was referred to her GP.
It was recommended that women whose dose of MPA was
increased to 5 mg because of bleeding in the first 90 days
remained on the higher dose until 3 months amenor-
rhoea had been achieved. Thereafter the dose could be
reduced to 2.5 mg, but should bleeding reoccur within 21
days of the dose reduction, it was recommended that the
patient resume taking 5 mg MPA.
• Bleeding that started after 90 days amenorrhoea on
active treatment.
Women with bleeding that started after 90 days of amen-
orrhoea on active treatment were referred immediately to
their GP unless the bleeding occurred within 21 days of a
treatment interruption, reduction in the dose of MPA
from 5 mg to 2.5 mg or following diarrhoea, vomiting or
a course of antibiotics. If one of these possible reasons
applied, the patient was monitored by the nurse and
referred to her GP if bleeding continued beyond 21 days.
• Persistent bleeding
Women with persistent bleeding for which no pathologi-
cal cause was found were offered second-line treatment
using Premique Cycle. Women with a uterus taking sec-
ond-line treatment who reported bleeding which was
heavier than their monthly menstrual bleed had been pre-
menopause or of longer duration were referred to the GP
for investigation.
Vaginal bleeding in women with a hysterectomy
Women with a hysterectomy (sub-total or total) reporting
vaginal bleeding were referred immediately to their GP for
investigation.
Discontinuation of trial treatment
Permanent discontinuation of trial treatment was
required if any of the exclusion criteria for the trial were
confirmed during follow up. If participants developed
symptomatic or active gall bladder disease a temporary
interruption of treatment was made and if the participant
subsequently had a cholecystectomy they were invited to
recommence trial treatment. A temporary interruption of
treatment was required to investigate sudden loss of
vision, onset of proptosis or diplopia.
When trial outcomes occurred that were not trial exclu-
sions (myocardial infarction, unstable hospitalised
angina pectoris, cerebrovascular accident, subarachnoid
haemorrhage, TIA, osteoporotic fractures) participants
were able to remain on their allocated treatment to con-
tribute to other outcomes. However, a temporary inter-
ruption of treatment could be initiated at the discretion of
the GP or other clinician or by the participant. To reduce
the risk of venous thromboembolism, a temporary inter-
ruption could be made during hospitalisation and follow-
ing accidents resulting in immobilisation. Trial treatment
could also be discontinued at the discretion of the GP for
symptoms possibly associated with trial treatment, other
medical or non-medical reasons. Participants were free to
initiate withdrawal from the trial or temporary interrup-
tion of treatment without giving a reason.
GPs and participants were encouraged to try a temporary
interruption of treatment first and were requested to dis-
continue treatment permanently only after consultation
with the trial clinician and after all efforts had been made
to keep the patient on randomised treatment.
Minimising loss to follow up
All patients who discontinued trial treatment were fol-
lowed up and every effort was made to contact patients
after non-attendance at follow up appointments to mini-
mise losses to follow up. Where participants did not
attend for visits, but had given permission for their medi-
cal records to be accessed, annual and final searches were
undertaken.
Sample size and comparisons
The original minimum sample size for WISDOM, set at
the time of the grant application, was 18000, to detect,
with 80% power at the 5% level of significance, a 25%
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decrease in ischaemic heart disease (excluding unstable
angina) and stroke over ten years comparing, in women
aged 50–64 years at randomisation, those randomised to
HRT (combined HRT plus estrogen only HRT) with those
randomised to placebo. It was agreed that an actual
recruitment target of 23000, to include recruitment from
countries other than the UK, was feasible.
The primary outcome was subsequently changed to
exclude stroke and include unstable angina and the age
range was extended up to 69 years. Other assumptions
were modified reflecting falling coronary event rates in the
general population, new information from the Women's
Health Initiative (personal communication to MRC WIS-
DOM Steering Group) on likely times to treatment effects
and fall off in treatment effects after discontinuation of
treatment, and revised estimates for withdrawal from ran-
domised treatment. Sample size calculations were revised
to calculate what might be detected with a sample of
23000. Comparing combined HRT with placebo it was
estimated that WISDOM would have 80% power at the
5% level of significance to detect at ten years:
• for cardiovascular disease (including unstable angina), a
29% reduction from a placebo event rate of 39/1000;
• for all osteoporotic fractures, a 20% reduction from a
placebo event rate of 95/1000; and
• for breast cancer, a 40% increase from a placebo event
rate of 36/1000.
For cardiovascular disease calculation of event rates in the
trial population not receiving active treatment incorpo-
rated the following.
• Over the period 1997 to 2010 an assumed reduction in
mortality from IHD of 40% and drop in incidence rate of
20%.
• Withdrawal from randomised treatment by 10% of par-
ticipants in the first year of treatment, 7% in year 2, 4% in
year 3, 3% in year 4 and 2% in years 5 – 10, giving a total
withdrawal at some stage of 36%. An approximation to
the change in the event rate observed can be made assum-
ing 70% of HRT group have been on treatment for full 10
years and 30% have no treatment.
• For IHD 2.5 non-fatal events occurring for each fatal
event as suggested by the MONICA study, total numbers
(i.e. fatal plus non-fatal) then being derived from ONS
age-specific mortality rates in 1997.
• In the absence of reliable estimates of the incidence of
unstable angina for women in the relevant age group, the
best estimate was a rate of about 1 per 1000 women per
year. Over the ten years of the trial this rate would gener-
ate 9.7 unstable angina events per 1000 women entered.
However, it was estimated that 50% of these would lead
to myocardial infarction, giving an incidence of inde-
pendent unstable angina events of 4.8 per 1000 women.
• A healthy volunteer effect leading to event rates only
67% of those based on the sum of fatal and non-fatal epi-
sodes in the general population.
• Based on feasibility studies and current use of and inter-
est in HRT 20% of the trial population being in the age
range 65–69 years and 80% being distributed equally
across the three five year age bands, 50–54, 55–59, 60–64
years.
• A 3 year recruitment, which would give 33% of women
in study for 11 years, 33% in study for 10 years and 33%
of women in study for 9 years.
Using these assumptions the average probability of a
major cardiovascular event within ten years in women in
the age group 50–69 was estimated to be 0.039.
For the main comparison of HRT versus no HRT, only
women who could be randomised to receive placebo
could contribute (strata 1 and 3, Figure 3). Based on feasi-
bility studies the proportions expected in the different
strata were: stratum 1, 58% equally divided between com-
bined HRT and placebo; stratum 2, 22% equally divided
between combined HRT and estrogen-only HRT; stratum
3, 20% equally divided between combined HRT, estrogen-
only HRT and placebo. The majority of women on HRT
(~84%) would be on combined HRT. Of the total sample
size, 78% would be used to compare HRT with placebo
(the remaining 22% contributing to the ERT v PERT com-
parison). The sample sizes have been calculated to achieve
significance in a combined HRT versus no HRT compari-
son, with equal numbers of women randomised to com-
bined HRT and placebo. The target sample size of 22300
gives statistical power of 80% (at 5% level of significance)
to detect a reduction of 29% in the cardiovascular end-
point. Power for an HRT (combined HRT plus estrogen
only HRT) versus no HRT comparison would be slightly
increased by the inclusion of hysterectomised patients
(within stratum 3) randomised to estrogen-only HRT.
A 29% reduction in risk in those taking HRT would reduce
the average probability of a cardiovascular event to 0.028,
an absolute reduction of 0.011. If this was achieved then
treating 89 women for ten years with HRT would prevent
one cardiovascular event. Allowing for withdrawals as
described above the average probability of an event would
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be 0.031 and an intention to treat 125 women for ten
years with HRT would prevent one cardiovascular event.
For a direct comparison of estrogen only HRT with com-
bined HRT, approximately 8,000 women could contrib-
ute: those in stratum 2 together with those in stratum 3
randomised to HRT. With equal numbers being ran-
domised to estrogen only HRT and combined HRT a 45%
difference in cardiovascular events between the groups
could be detected with statistical power of 80% (at 5%
level of significance).
For the osteoporotic fracture and cancer outcomes it was
assumed that the final assessment would be made five
years after the end of treatment. No assumptions were
made about HRT use following the end of the trial.
In estimating the trial event rate for fractures it was
assumed there would be no change in the current fracture
rate until 2010. Incidence rates for hip fracture were esti-
mated using figures from the European Report on Oste-
oporosis, 1998. No trend figures were available and no
trend was assumed. Rates were reduced by 20% for a
healthy volunteer effect. At the end of the 5 year post treat-
ment follow-up period, 27 hip fractures per 1000 women
recruited would be expected. Based on published data the
risk ratio was estimated as 0.7 in the first year on treat-
ment, 0.6 for second year, 0.5 for years 3 – 10, gradually
increasing back to 1 after treatment ends. This would give
an expected reduction in events of 26% from 27 per 1000,
to 20 per 1000 women recruited. The sample size of
23000 would be able to detect only a larger reduction in
hip fractures of 36% with 80% power at the 5% level of
significance. We therefore looked at all osteoporotic frac-
tures. As there were no UK incidence rates available for all
osteoporotic fractures we assumed the same ratio between
hip and all osteoporotic fractures as in US. Rates were
reduced by 20% for a healthy volunteer effect. At the end
of 5 year post treatment follow-up period, 95 fractures per
1000 women recruited would be expected. Assuming the
risk ratio for all fractures was similar to that for hip frac-
tures a 28% decrease in event rate at 5 year follow-up
would be expected. A sample size of 23000 could detect a
smaller reduction of 20% for all osteoporotic fractures.
The incidence rate for breast cancer rose by about 50% in
those aged 50 -69 years over the period 1982–1992. In
estimating the trial event rate for breast cancer it was
assumed that no further increase would occur. Incidence
rates were adjusted down by 10% to allow for the fact that
those with near relatives having had breast cancer were
unlikely to enter the trial. No other healthy volunteer
effect was allowed for. With these assumptions, the
expected trial event rate for breast cancer at the end of the
5 year post treatment follow-up period was 36 per 1000
women entered. With a sample size of 23000 it would be
possible to detect a 40% increase from a placebo event
rate of 36/1000 women-years. This was much higher than
the expected increased risk; observational studies sug-
gested that the risk ratio increased by 2.3% for each year
on treatment and reduced by the same amount after treat-
ment ends. This would give an expected 11% increase in
event rate at 5 years follow-up, an increase from 36 per
1000 women to 40 per 1000 women recruited. It was thus
anticipated that WISDOM data would be most appropri-
ately used to contribute to a meta-analysis of the effect of
HRT on breast cancer.
The incidence rates for colorectal, ovarian, cervical and
endometrial cancers are low and WISDOM would be able
to detect only very large increases/decreases associated
with HRT use. Estimated event rates for other cancers at 5
year post treatment follow-up were: colorectal 19 per
1000 women recruited; ovarian 8 per 1000 women
recruited; cervical 3 per 1000 women recruited; and
endometrial 6 per 1000 women recruited.
Statistical methods
Follow-up time will be calculated for each participant
from date of randomisation until the first among: date of
outcome, date of death, or 22 October 2002 (when the
trial was formally halted). The intention to treat principle
will be adopted when assessing treatment effects, partici-
pants being classified according to randomisation group
and analyses being made comparing HRT (combined HRT
plus estrogen only HRT) or combined HRT alone with
placebo, and combined HRT with estrogen only HRT. To
account for the prospective nature of the data, Kaplan-
Meier outcome-free survival curves will be computed and
Cox proportional hazard models fitted (after graphically
checking the underlying proportional hazards assump-
tions). The results will be reported as estimated hazard
ratios for the effect of HRT versus placebo, combined HRT
versus placebo or combined HRT versus ERT, (with 95%
confidence intervals), with associated likelihood ratio
tests for their significance [62].
Results
The trial was prematurely closed during recruitment fol-
lowing publication of early results from the Women's
Health Initiative. At the time of closure, 56583 had been
screened, 8980 entered run-in, and 5694 (26% of target of
22300) randomised. Those women randomised had
received a mean of one year of therapy, mean age was 62.8
years and total follow-up time was 6491 person years. The
results will be published separately.
Discussion
The background and history of the WISDOM trial and its
early closure have been described elsewhere [63]. It is
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however fitting to conclude this protocol paper by reflect-
ing on some of the difficulties encountered in setting up a
project of this size and complexity and the lessons that
may be learned.
WISDOM was beset with delays. From the initial recogni-
tion in 1988 that research was needed, to agreement that
a randomised controlled trial was the appropriate design,
took the UK MRC and Departments of Health two years.
A further six years elapsed from the start of the commis-
sioned pilot studies in 1990, to the release of funding for
the main trial, despite the demonstration by early 1993
that the trial was feasible in the UK and other European
countries. The factors contributing to the delay were
understandable concerns about cost, but also opposition
by many UK clinicians and scientists working in the men-
opause area on the grounds that the risk benefit profile of
HRT had clearly been shown to be favourable by observa-
tional studies. They argued that long-term HRT would
reduce osteoporotic fractures and cardiovascular disease
and was unlikely to have a significant effect on breast can-
cer and hence that the funds for the trial would be better
spent elsewhere. While the UK was considering ways to
reduce or spread costs beyond the UK, and answer the
concerns of those opposed to the trial, the WHI trial in the
US was conceived, funded and started. Once WHI was in
place other countries were no longer prepared to commit
funds to WISDOM, despite the successful European feasi-
bility studies and commitment by senior clinicians inter-
nationally. Thus the design eventually funded in the UK
by MRC and the Departments of Health was an affordable
compromise, not the optimum design originally pro-
posed (recently postmenopausal women and two HRT
preparations). In the future, when key questions require
very costly trials, international collaboration and joint
funding by several countries, including the UK and the
US, should be pursued. For HRT, had this been possible,
the original design for a trial of two types of oestrogen and
two cHRT preparations in women aged 50–60 years might
have been undertaken. Two important questions which
remain unanswered: i) the effect of long-term HRT started
close to the menopause and ii) whether there are differ-
ences between different types of HRT could then have
been addressed.
The set-up and recruitment phase for WISDOM also took
longer than anticipated. A decision was made to collect
data directly on to laptop computers and download to the
co-ordinating centre and to undertake all the design and
programming in house. We aimed for technical perfection
and the system eventually incorporated a sophisticated
real time patient management program and was the pro-
totype for data collection in other trials in the MRC GPRF.
This worked extremely well and was one of the success
stories of the trial, but it resulted in a tendency to agree to
collect data on more and more outcomes of interest for
additional sub-studies in order to explore fully the poten-
tial risks and benefits of HRT. WISDOM would have pro-
gressed more rapidly if we had restricted data collection to
the main outcomes and had devolved more of the deci-
sions about individual patient care to the clinicians at the
participating sites.
During the six years delay between the application for
funding in 1993 and the start of recruitment in 1999
women's use of and perceptions about HRT had changed
and UK general practice had been re-organised. This
impacted on the trial in that the window of opportunity
for rapid recruitment had been lost. Though new strate-
gies were proving successful and have since been used in
other trials, recruitment was slower and more costly than
anticipated. While it is unlikely that, had WISDOM
recruited a greater proportion of its target before the WHI
results were published, closure could have been avoided,
younger, more recently post-menopausal women would
have been included (the strategy was to recruit older age
groups first) adding new information not available from
the WHI trials.
The WISDOM experience leads to some simple messages.
The larger a trial is the more simple it needs to be to ensure
cost effective and timely delivery. Investigators should
resist gathering data for others, which, while valuable, dis-
tracts from the main purpose of the trial. When a trial is
very costly and beyond the resources of one country,
funders and investigators should make efforts to develop
international collaboration with joint funding. If it is not
feasible to undertake the optimum design because of lack
of funds, investigators should be sure that a compromise
design, recommended by funders, really does address the
key questions posed.
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